Semiquantitative analysis of brain metabolism in patients with paraneoplastic neurologic syndromes

Allison Clapp, Christopher Hunt, Geoffrey Johnson, Patrick Peller

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

PURPOSE: The objective of this study was to evaluate brain metabolism with F-FDG-PET in patients with definite or possible paraneoplastic neurologic syndromes (PNS) using qualitative assessment and semiquantitative measurements with subsequent correlation with MRI. METHODS: The institutional review board approved this Health Insurance Portability and Accountability Act-compliant study. A prospective PET database of patients referred for PNS between 2001 and 2010 was queried retrospectively and identified 102 patients who met the diagnostic criteria for PNS, had PET brain imaging, and lacked clinical or MRI evidence of an alternative diagnosis.Qualitative and semiquantitative evaluation of brain metabolism was obtained by 3-dimensional stereotactic surface projection and region-based analysis. Qualitative and semiquantitative assessment was performed blinded to clinical data. RESULTS: PET/CT demonstrated that 67 patients had abnormal brain glucose metabolism. Six categories of brain hypometabolism were identified: diffuse (36/67), cerebellar (10/67), basal ganglia (10/67), frontal (9/67), temporal (1/67), and occipital (1/67). The mean Z score of the cerebral cortex in diffuse hypometabolism was 1.65 (range, 0.25-3.46). For cerebellar hypometabolism, the mean Z score of the cerebellum was 2.31 (range, 0.52-4.54). In basal ganglia hypometabolism, the mean Z score was 2.53 (range, 1.78-3.89), and in frontal lobe hypometabolism, the mean Z score was 2.11 (range, 1.39-4.45). The majority (39/67, 62.9%) with abnormal glucose metabolism on PET had a normal MR. CONCLUSIONS: Patients with PNS frequently have abnormal brain metabolism on semiquantitative PET/CT. With semiquantitative analysis, we defined 6 common patterns of abnormalities, which often correlated with clinical symptoms. Both qualitative and semiquantitative analyses of brain glucose metabolism may be helpful in evaluating PNS, especially in patients with a normal MRI.

Original languageEnglish (US)
Pages (from-to)241-247
Number of pages7
JournalClinical Nuclear Medicine
Volume38
Issue number4
DOIs
StatePublished - Apr 2013

Fingerprint

Nervous System Paraneoplastic Syndromes
Brain
Basal Ganglia
Glucose
Health Insurance Portability and Accountability Act
Research Ethics Committees
Frontal Lobe
Neuroimaging
Cerebral Cortex
Cerebellum
Databases

Keywords

  • 3DSSP
  • brain metabolism
  • paraneoplastic neurologic syndromes
  • PET

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging

Cite this

Semiquantitative analysis of brain metabolism in patients with paraneoplastic neurologic syndromes. / Clapp, Allison; Hunt, Christopher; Johnson, Geoffrey; Peller, Patrick.

In: Clinical Nuclear Medicine, Vol. 38, No. 4, 04.2013, p. 241-247.

Research output: Contribution to journalArticle

Clapp, Allison ; Hunt, Christopher ; Johnson, Geoffrey ; Peller, Patrick. / Semiquantitative analysis of brain metabolism in patients with paraneoplastic neurologic syndromes. In: Clinical Nuclear Medicine. 2013 ; Vol. 38, No. 4. pp. 241-247.
@article{7b92c12ffcc346c6841fe08d9ef30644,
title = "Semiquantitative analysis of brain metabolism in patients with paraneoplastic neurologic syndromes",
abstract = "PURPOSE: The objective of this study was to evaluate brain metabolism with F-FDG-PET in patients with definite or possible paraneoplastic neurologic syndromes (PNS) using qualitative assessment and semiquantitative measurements with subsequent correlation with MRI. METHODS: The institutional review board approved this Health Insurance Portability and Accountability Act-compliant study. A prospective PET database of patients referred for PNS between 2001 and 2010 was queried retrospectively and identified 102 patients who met the diagnostic criteria for PNS, had PET brain imaging, and lacked clinical or MRI evidence of an alternative diagnosis.Qualitative and semiquantitative evaluation of brain metabolism was obtained by 3-dimensional stereotactic surface projection and region-based analysis. Qualitative and semiquantitative assessment was performed blinded to clinical data. RESULTS: PET/CT demonstrated that 67 patients had abnormal brain glucose metabolism. Six categories of brain hypometabolism were identified: diffuse (36/67), cerebellar (10/67), basal ganglia (10/67), frontal (9/67), temporal (1/67), and occipital (1/67). The mean Z score of the cerebral cortex in diffuse hypometabolism was 1.65 (range, 0.25-3.46). For cerebellar hypometabolism, the mean Z score of the cerebellum was 2.31 (range, 0.52-4.54). In basal ganglia hypometabolism, the mean Z score was 2.53 (range, 1.78-3.89), and in frontal lobe hypometabolism, the mean Z score was 2.11 (range, 1.39-4.45). The majority (39/67, 62.9{\%}) with abnormal glucose metabolism on PET had a normal MR. CONCLUSIONS: Patients with PNS frequently have abnormal brain metabolism on semiquantitative PET/CT. With semiquantitative analysis, we defined 6 common patterns of abnormalities, which often correlated with clinical symptoms. Both qualitative and semiquantitative analyses of brain glucose metabolism may be helpful in evaluating PNS, especially in patients with a normal MRI.",
keywords = "3DSSP, brain metabolism, paraneoplastic neurologic syndromes, PET",
author = "Allison Clapp and Christopher Hunt and Geoffrey Johnson and Patrick Peller",
year = "2013",
month = "4",
doi = "10.1097/RLU.0b013e3182815f28",
language = "English (US)",
volume = "38",
pages = "241--247",
journal = "Clinical Nuclear Medicine",
issn = "0363-9762",
publisher = "Lippincott Williams and Wilkins",
number = "4",

}

TY - JOUR

T1 - Semiquantitative analysis of brain metabolism in patients with paraneoplastic neurologic syndromes

AU - Clapp, Allison

AU - Hunt, Christopher

AU - Johnson, Geoffrey

AU - Peller, Patrick

PY - 2013/4

Y1 - 2013/4

N2 - PURPOSE: The objective of this study was to evaluate brain metabolism with F-FDG-PET in patients with definite or possible paraneoplastic neurologic syndromes (PNS) using qualitative assessment and semiquantitative measurements with subsequent correlation with MRI. METHODS: The institutional review board approved this Health Insurance Portability and Accountability Act-compliant study. A prospective PET database of patients referred for PNS between 2001 and 2010 was queried retrospectively and identified 102 patients who met the diagnostic criteria for PNS, had PET brain imaging, and lacked clinical or MRI evidence of an alternative diagnosis.Qualitative and semiquantitative evaluation of brain metabolism was obtained by 3-dimensional stereotactic surface projection and region-based analysis. Qualitative and semiquantitative assessment was performed blinded to clinical data. RESULTS: PET/CT demonstrated that 67 patients had abnormal brain glucose metabolism. Six categories of brain hypometabolism were identified: diffuse (36/67), cerebellar (10/67), basal ganglia (10/67), frontal (9/67), temporal (1/67), and occipital (1/67). The mean Z score of the cerebral cortex in diffuse hypometabolism was 1.65 (range, 0.25-3.46). For cerebellar hypometabolism, the mean Z score of the cerebellum was 2.31 (range, 0.52-4.54). In basal ganglia hypometabolism, the mean Z score was 2.53 (range, 1.78-3.89), and in frontal lobe hypometabolism, the mean Z score was 2.11 (range, 1.39-4.45). The majority (39/67, 62.9%) with abnormal glucose metabolism on PET had a normal MR. CONCLUSIONS: Patients with PNS frequently have abnormal brain metabolism on semiquantitative PET/CT. With semiquantitative analysis, we defined 6 common patterns of abnormalities, which often correlated with clinical symptoms. Both qualitative and semiquantitative analyses of brain glucose metabolism may be helpful in evaluating PNS, especially in patients with a normal MRI.

AB - PURPOSE: The objective of this study was to evaluate brain metabolism with F-FDG-PET in patients with definite or possible paraneoplastic neurologic syndromes (PNS) using qualitative assessment and semiquantitative measurements with subsequent correlation with MRI. METHODS: The institutional review board approved this Health Insurance Portability and Accountability Act-compliant study. A prospective PET database of patients referred for PNS between 2001 and 2010 was queried retrospectively and identified 102 patients who met the diagnostic criteria for PNS, had PET brain imaging, and lacked clinical or MRI evidence of an alternative diagnosis.Qualitative and semiquantitative evaluation of brain metabolism was obtained by 3-dimensional stereotactic surface projection and region-based analysis. Qualitative and semiquantitative assessment was performed blinded to clinical data. RESULTS: PET/CT demonstrated that 67 patients had abnormal brain glucose metabolism. Six categories of brain hypometabolism were identified: diffuse (36/67), cerebellar (10/67), basal ganglia (10/67), frontal (9/67), temporal (1/67), and occipital (1/67). The mean Z score of the cerebral cortex in diffuse hypometabolism was 1.65 (range, 0.25-3.46). For cerebellar hypometabolism, the mean Z score of the cerebellum was 2.31 (range, 0.52-4.54). In basal ganglia hypometabolism, the mean Z score was 2.53 (range, 1.78-3.89), and in frontal lobe hypometabolism, the mean Z score was 2.11 (range, 1.39-4.45). The majority (39/67, 62.9%) with abnormal glucose metabolism on PET had a normal MR. CONCLUSIONS: Patients with PNS frequently have abnormal brain metabolism on semiquantitative PET/CT. With semiquantitative analysis, we defined 6 common patterns of abnormalities, which often correlated with clinical symptoms. Both qualitative and semiquantitative analyses of brain glucose metabolism may be helpful in evaluating PNS, especially in patients with a normal MRI.

KW - 3DSSP

KW - brain metabolism

KW - paraneoplastic neurologic syndromes

KW - PET

UR - http://www.scopus.com/inward/record.url?scp=84875215699&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84875215699&partnerID=8YFLogxK

U2 - 10.1097/RLU.0b013e3182815f28

DO - 10.1097/RLU.0b013e3182815f28

M3 - Article

VL - 38

SP - 241

EP - 247

JO - Clinical Nuclear Medicine

JF - Clinical Nuclear Medicine

SN - 0363-9762

IS - 4

ER -